Klebsiella pneumoniae
Klebsiella pneumoniae | |
---|---|
K. pneumoniae on a MacConkey agar plate | |
Scientific classification | |
Domain: | Bacteria |
Phylum: | Pseudomonadota |
Class: | Gammaproteobacteria |
Order: | Enterobacterales |
Family: | Enterobacteriaceae |
Genus: | Klebsiella |
Species: | K. pneumoniae
|
Binomial name | |
Klebsiella pneumoniae (Schroeter 1886) Trevisan 1887
| |
Subspecies | |
Klebsiella pneumoniae is a
Although found in the normal flora of the mouth, skin, and intestines,
It naturally occurs in the soil, and about 30% of strains can fix nitrogen in anaerobic conditions.[2] As a free-living diazotroph, its nitrogen-fixation system has been much-studied, and is of agricultural interest, as K. pneumoniae has been demonstrated to increase crop yields in agricultural conditions.[3]
It is closely related to
History
The genus Klebsiella was named after the German microbiologist Edwin Klebs (1834–1913).[citation needed] It is also known as Friedlander's bacillum in honor of Carl Friedländer, a German pathologist, who proposed that this bacterium was the etiological factor for the pneumonia seen especially in immunocompromised individuals such as people with chronic diseases or alcoholics.
Community-acquired pneumonia caused by Klebsiella pneumoniae may occasionally be called Friedländer's pneumonia.[4]
Epidemiology
Illness most commonly affects middle-aged and older men more often than women with debilitating diseases. This patient population is believed to have impaired respiratory host defenses, including persons with
In addition to pneumonia, Klebsiella can also cause infections in the
Research conducted at King's College, London has implicated molecular mimicry between HLA-B27 and two Klebsiella surface molecules as the cause of ankylosing spondylitis.[5]
Klebsiella ranks second to
Klebsiella pneumonia
The most common condition caused by Klebsiella bacteria outside the hospital is pneumonia, typically in the form of bronchopneumonia and also bronchitis. These patients have an increased tendency to develop lung abscesses, cavitation, empyema, and pleural adhesions. It has a death rate around 50%, even with antimicrobial therapy.[8]
Pathophysiology
It is typically due to
Signs and symptoms
Individuals with Klebsiella pneumoniae tend to cough up a characteristic sputum, as well as having fever, nausea, tachycardia, and vomiting. Klebsiella pneumoniae tends to affect people with underlying conditions, such as alcoholism.[9]
Diagnosis
In terms of the diagnosis of Klebsiella pneumoniae the following can be done to determine if the individual has this infection, with the addition of susceptibility testing to identify drug-resistant organisms:[11][9]
- Blood culture
- CBC
- Sputum(culture)
- Radiography(chest)
- CT scan
Treatment
Treatment for Klebsiella pneumoniae is by
Klebsiella possesses
Hypervirulent Klebsiella pneumonia
Hypervirulent (hvKp) is a rather recent K pneumoniae variant that is significantly more virulent than classical K. pneumoniae (cKp). While cKp is an opportunistic pathogen responsible for nosocomial infections that usually affect immunocompromised patients, hvKp is clinically more concerning since it also causes disease in healthy individuals and can infect virtually every site of the body. The genetic traits that lead to this pathotype are included in a large virulence plasmid and potentially on additional conjugative elements.[17]
These newly identified strains were described to overproduce capsule components and siderophores for iron acquisition, among other factors.[18] Although initial studies showed that hvKp is rather susceptible to antibiotic treatment, it has been recently shown that such strains can acquire resistance plasmids and become multiresistant to a variety of antibiotics.[18][19][20]
It originated from Asia, having a high mortality rate among the population. It often spreads to central nervous system and eye causing endophthalmitis, nonhepatic abscesses, pneumonia, necrotizing fasciitis, and meningitis. One visual trait of these strains is hypermucoviscous phenotype and a string test can be used to help the diagnosis.[21] Further examinations and treatments are made on a case-by-case basis, as there are currently no international guidelines.[22]
Transmission
To get a K. pneumoniae infection, a person must be exposed to the
Resistant strains
Klebsiella organisms are often resistant to multiple antibiotics. Current evidence implicates
Infection with
CRKP is resistant to almost all available antimicrobial agents, and infections with CRKP have caused high rates of morbidity and mortality, in particular among persons with prolonged hospitalization and those critically ill and exposed to invasive devices (e.g., ventilators or central venous catheters). The concern is that carbapenem is often used as a drug of last resort when battling resistant bacterial strains. New slight mutations could result in infections for which healthcare professionals can do very little, if anything, to treat patients with resistant organisms.
A number of mechanisms cause carbapenem resistance in the Enterobacteriaceae. These include hyperproduction of ampC
The extent and prevalence of CRKP within the environment is currently unknown. The mortality rate is also unknown, but has been observed to be as high as 44%.[34] The Centers for Disease Control and Prevention released guidance for aggressive infection control to combat CRKP:
- Place all patients colonized or infected with carbapenemase-producing Enterobacteriaceae on contact precautions. Acute-care facilities are to establish a protocol, in conjunction with the guidelines of the Clinical and Laboratory Standards Institute, to detect nonsusceptibility and carbapenemase production in Enterobacteriaceae, in particular Klebsiella spp. and Escherichia coli, and immediately alert epidemiology and infection-control staff members if identified. All acute-care facilities are to review microbiology records for the preceding 6–12 months to ensure that there have not been previously unrecognized CRE cases. If they do identify previously unrecognized cases, a point prevalence survey (a single round of active surveillance cultures) in units with patients at high risk (e.g., intensive-care units, units where previous cases have been identified, and units where many patients are exposed to broad-spectrum antimicrobials) is needed to identify any additional patients colonized with carbapenem-resistant or carbapenemase-producing Klebsiella spp. and E. coli. When a case of hospital-associated CRE is identified, facilities should conduct a round of active surveillance testing of patients with epidemiologic links to the CRE case (e.g., those patients in the same unit or patients having been cared for by the same health-care personnel).[35]
In 2019, there were 192,530 global deaths attributed to resistant strains of Klebsiella pneumoniae. [36]
3GC | 4GC | Amino-glycosides | Amino-penicillin | Anti-pseudomonal | BL−BLI | Carbapenems | Fluoro-quinolones | Macrolide | MDR & XDR | Meticillin | Mono INH | Mono RIF | Penicillin | TMP-SMX | Vancomycin | Total | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acinetobacter baumannii | 6,860 | 3,280 | 10,400 | 13,300 | 811 | 57,700 | 40,000 | 132,351 | |||||||||
Citrobacter spp | 1,840 | 1,340 | 411 | 2,170 | 2,300 | 2,510 | 10,571 | ||||||||||
Enterobacter spp | 5320 | 3070 | 9550 | 15,300 | 7,800 | 4,650 | 45,690 | ||||||||||
Enterococcus faecalis | 26,800 | 3,420 | 30,220 | ||||||||||||||
Enterococcus faecium | 37,200 | 14,300 | 51,500 | ||||||||||||||
Other enterococci | 12,200 | 2,200 | 14,400 | ||||||||||||||
Escherichia coli | 59,900 | 11,700 | 10,500 | 21,300 | 29,500 | 56,000 | 30,200 | 219,100 | |||||||||
Group A Streptococcus | 3,630 | 3,630 | |||||||||||||||
Group B Streptococcus | 11,500 | 13,500 | 799 | 25,799 | |||||||||||||
Haemophilus influenzae | 2,470 | 4,290 | 6,760 | ||||||||||||||
Klebsiella pneumoniae | 50,100 | 26,300 | 7,930 | 55,700 | 29,000 | 23,500 | 192,530 | ||||||||||
Morganella spp | 168 | 154 | 427 | 749 | |||||||||||||
Mycobacterium tuberculosis | 69,810 | 11,600 | 3,350 | 84,760 | |||||||||||||
Proteus spp | 4,730 | 887 | 1,330 | 2,970 | 1,620 | 11,537 | |||||||||||
Pseudomonas aeruginosa | 10,400 | 4,370 | 3,010 | 10,300 | 38,100 | 18,300 | 84,480 | ||||||||||
S Paratyphi | 4,040 | 64 | 4,104 | ||||||||||||||
S Typhi | 17,200 | 6,460 | 23,660 | ||||||||||||||
Non-typhoidal Salmonella | 5,620 | 5,620 | |||||||||||||||
Serratia spp | 1,100 | 2,610 | 953 | 2,450 | 1,080 | 8,193 | |||||||||||
Shigella spp | 5,990 | 5,990 | |||||||||||||||
Staphylococcus aureus | 2,480 | 15,900 | 19,600 | 121,000 | 18,700 | 3,120 | 180,800 | ||||||||||
Streptococcus pneumonia | 3,330 | 2,040 | 41,900 | 11,200 | 12,500 | 12,400 | 38,700 | 122,070 | |||||||||
Total | 140,898 | 17,074 | 56,731 | 16,120 | 37,800 | 32,081 | 242,950 | 305,737 | 49,230 | 76,334 | 121,000 | 11,600 | 3,350 | 12,199 | 117,370 | 23,040 | 1,264,514 |
Local outbreaks
Israel 2007-2008. A nationwide outbreak of CRE in Israel peaked in March, 2007 at 55.5 cases per 100,000 patient days and necessitated a nationwide treatment plan. The intervention entailed physical separation of all CRE carriers and appointment of a task force to oversee efficacy of isolation by closely monitoring hospitals and intervening when necessary. After the treatment plan (measured in May, 2008), the number of cases per 100,000 patient days decreased to 11.7. The plan was effective because of strict hospital compliance, wherein each was required to keep detailed documentation of all CRE carriers. In fact, for each increase in compliance by 10%, incidence of cases per 100,000 patient days decreased by 0.6. Therefore, containment on a nationwide scale requires nationwide intervention.[37]
Nevada 2016. In mid-August 2016, a resident of Washoe County was hospitalized in Reno due to a CRE (specifically Klebsiella pneumoniae) infection. In early September of the same year, she developed septic shock and died. On testing by CDC an isolate from the patient was found to be resistant to all 26 antibiotics available in the US, including drug of last resort colistin.[38] It is believed she may have picked up the microbe while hospitalized in India for two years due to a broken right femur and subsequent femur and hip infections.[39][40][41]
Antimicrobial resistance gene transfer
Klebsiella pneumoniae carries a large number of anti-microbial resistance genes (AMR genes). These genes are transferred via plasmids from and to other human pathogens. One human pathogen that commonly acquires AMR genes from Klebsiella pneumoniae is Salmonella.[citation needed] This could help with treatment of salmonella infections due to having knowledge of possible antibiotic resistance data.[citation needed]
The majority of AMR genes in Klebsiella pneumoniae are plasmid-borne. An example of a niche would be soil, often considered a hotspot for gene transfer.[citation needed]
Total AMR genes per spp | Average plasmids | |
---|---|---|
Acinetobacter baumannii | 278 | 1.5 |
Pseudomonas aeruginosa | 263 | 0 |
Klebsiella pneumoniae | 410 | 2.5 |
Enterobacter cloacae | 277 | 2.2 |
Escherichia coli | 204 | 1 |
The table shows the number of AMR genes and plasmids (per strain or subspecies) compared to other common bacteria species.[42]
Prevention
To prevent spreading Klebsiella infections between patients, healthcare personnel must follow specific infection-control precautions,[24] which may include strict adherence to hand hygiene (preferably using an alcohol based hand rub (60–90%) or soap and water if hands are visibly soiled. Alcohol based hand rubs are effective against these Gram-negative bacilli)[43] and wearing gowns and gloves when they enter rooms where patients with Klebsiella–related illnesses are housed. Healthcare facilities also must follow strict cleaning procedures to prevent the spread of Klebsiella.[24]
To prevent the spread of infections, patients also should clean their hands very often, including:
- Before preparing or eating food
- Before touching their eyes, nose, or mouth
- Before and after changing wound dressings or bandages
- After using the restroom
- After blowing their nose, coughing, or sneezing
- After touching hospital surfaces such as bed rails, bedside tables, doorknobs, remote controls, or the phone[24]
Treatment
K. pneumoniae can be treated with antibiotics if the infections are not
Research
Multiple drug-resistant K. pneumoniae strains have been killed in vivo by intraperitoneal, intravenous, or intranasal administration of phages in laboratory tests.[45] Resistance to phages is not likely to be as troublesome as to antibiotics as new infectious phages are likely to be available in environmental reservoirs. Phage therapy can be used in conjunction with antibiotics, to supplement their activity instead of replacing it altogether.[46]
Vaccine development
New data sources outlining the global burden of K. pneumoniae and drug-resistant forms are expected to build momentum into prophylactic vaccine development.[47] The recent 2022 IHME study showed that in 2019 K. pneumoniae was responsible for 790,000 deaths [571,000–1,060,000] in all age groups across 11 infectious syndromes. Importantly, in Sub-saharan Africa K. pneumoniae was responsible for 124,000 [89,000–167,000] neonatal deaths due to bloodstream infections. Based on these and other data, a newly developed prophylactic vaccine would ideally be designed to prevent invasive K. pneumoniae disease in both vulnerable persons but also as a maternal vaccine to prevent neonatal sepsis and global demand assessments have been published.[48] As of June 2023, one single clinical development program for a K. pneumoniae vaccine [Kleb4V/GSK4429016A] was in a Phase 1/2 study in healthy adults aged 18–70 yrs (n=166) [Clinical trials identifier: NCT04959344]. The vaccine is an O-antigen based conjugate where the specific O-antigens in the vaccine remain undisclosed [Michael Kowarik, LimmaTech Biologics, World Vaccine Congress EU, 2022] although only a limited number of O-serotypes can account for a high proportion of clinical isolates.[49] A recent Q1 2024 GSK Corporate R&D pipeline update showed that Kleb4V/GSK4429016A had been removed. The status of the program is now subject to verification.
References
- ISBN 978-0-8385-8529-0.
- ISBN 978-0-521-64047-3.
- doi:10.1071/PP01045.
- ISBN 978-0-323-46119-1. Retrieved 14 January 2017.
- S2CID 43456525.
- ^ "Female Urinary Tract Infection" (PDF). Medical Diagnostic Laboratories, L.L.C. Archived from the original (PDF) on 2020-10-15. Retrieved 2020-05-06.
- ^ Groopman J (2008-08-11). "Superbugs". The New Yorker. Retrieved 2013-07-07.
The new generation of resistant infections is almost impossible to treat.
- PMID 36536710.
- ^ a b c "Aspiration Pneumonia Symptoms. Treatment and Information | Patient". Patient. Retrieved 13 January 2017.
- ^ a b "Klebsiella species – GOV.UK". www.gov.uk. Retrieved 13 January 2017.
- ^ a b c Klebsiella Infections at eMedicine
- PMID 25340836.
- ISBN 978-1-4200-1684-0. Retrieved 13 January 2017.
- PMID 23260464.
- PMID 17307769.
- ^ "Klebsiella pneumoniae in Healthcare Settings". Centers for Disease Control and Prevention. Retrieved 13 January 2017.
- PMID 31092506.
- ^ PMID 33897652.
- PMID 33329444. 581543.
- PMID 32921250.
- PMID 29930857.
- PMID 31092506.
- ^ "Carbapenem-resistant Enterobacteriaceae (CRE) Infection: Clinician FAQs". Cdc.gov. Retrieved 25 October 2017.
- ^ a b c d e "Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings 2007". Centers for Disease Control and Prevention. 19 February 2021. This article incorporates text from this source, which is in the public domain.
- PMID 24905728.
- S2CID 73938823.
- ^ "Superbatterio New Delhi: salgono a 147 i casi in Toscana" (in Italian). Il Tirreno. 13 December 2019. Retrieved 14 December 2019.
- PMID 21998425.
- S2CID 73444389.
- ^ Berrie C (2007-04-04). "Carbapenem-resistant Klebsiella pneumoniae outbreak in an Israeli hospital". Medscape. Medical News. WebMD. Retrieved 2013-07-07.
- PMC 90438.
- ^ Vastag B (2012-08-22). "'Superbug' stalked NIH hospital last year, killing six". The Washington Post. Archived from the original on 2012-12-23. Retrieved 2013-07-07.
- ^ "Public Health Agency of Canada (PHAC) – Agence de la sante publique du Canada (ASPC)". Phac-aspc.gc.ca. 2004-09-24. Retrieved 25 October 2017.
- PMID 18086836.
- PMID 19300408.
- ^ PMID 35065702. Retrieved 23 December 2023.
- PMID 21317398.
- ^ Gallagher J (13 January 2017). "Bug resistant to all antibiotics kills woman". BBC News. Retrieved 16 January 2017.
- ^ "Nevada woman dies of superbug resistant to all available US antibiotics". STAT. 12 January 2017. Retrieved 13 January 2017.
- ^ Belluz J. "A woman died from a superbug that outsmarted all 26 US antibiotics". Vox. Retrieved 13 January 2017.
- ^ "Superbug Killed Nevada Woman". Yahoo! News. Retrieved 13 January 2017.
- ^ PMID 29723841.
- ^ "Guidance : Infection Prevention and Control Measures for Healthcare Workers in All Healthcare Settings" (PDF). Phac-aspc.gc.ca. Retrieved 25 October 2017.
- PMID 28948123.
- PMID 1882608.
- ISBN 978-1-62100-851-4.
- ^ Institute of Health Metrics and Evaluation. Global Research on Antimicrobial Resistance, University of Washington. 2022. Accessed: https://vizhub.healthdata.org/microbe/?settings=eyIxIjoiYW1yIiwiMiI6ImJhciIsIjMiOiJhbXIiLCI0IjoyMiwiNSI6MSwiNiI6MSwiNyI6MSwiOCI6MSwiOSI6MSwiMTIiOjEsIjEzIjoxLCIxNCI6MSwiMTUiOjEsIjE2IjoyLCIxNyI6MywiMTgiOjIwMTksIjE5IjpmYWxzZSwiMjAiOnRydWUsIjIyIjoxfQ==
- ^ VacZine Analytics. MarketVIEW: Klebsiella pneumoniae vaccines. https://www.vaczine-analytics.com/products-marketviewVAMV087_klebsiella_pneumoniae_vaccines.asp
- ^ Trautmann M et al. O antigen seroepidemiology of Klebsiella clinical isolates and implications for immunoprophylaxis of Klebsiella infections. Vaccine. 22(7), 818–21 (2004)
External links
- Virtual museum of bacteria page on K. pneumoniae Archived 2017-02-11 at the Wayback Machine
- What're the complications of pneumonia? (health-cares.net)
- Klebsiella Infection (emedicine.com)
- Klebsiella Genome Projects from Genomes OnLine Database
- Klebsiella pneumoniae-Associated Vertebral Osteomyelitis After Laparoscopic Cholecystectomy
- Type strain of Klebsiella pneumoniae at BacDive – the Bacterial Diversity Metadatabase